Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How HIV resists eradication

R J Pomerantz1

  • 1Division of Infectious Diseases, Jefferson Medical College of Thomas Jefferson University, Philadelphia, USA.

Hospital Practice (1995)
|September 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retroviruses and opportunistic infections--eighth annual conference.

IDrugs : the investigational drugs journal·2005
Same author

AIDS Vaccine 2001. Advances in AIDS research.

IDrugs : the investigational drugs journal·2005
Same author

Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.

Gene therapy·2004
Same author

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.

Gene therapy·2004
Same author

Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels.

Infection·2004
Same author

The HIV-1 Vif protein: a paradigm for viral:cell interactions.

Cellular and molecular life sciences : CMLS·2003
Same journal

A rocking biologic prosthetic valve: <i>Cutibacterium acnes</i> prosthetic valve endocarditis.

Hospital practice (1995)·2026
Same journal

Diagnostic accuracy of the Wells score versus duplex ultrasound for deep vein thrombosis in a Ghanaian cohort.

Hospital practice (1995)·2026
Same journal

Examining the frequency and factors related to the occurrence of deep vein thrombosis (DVT) in patients undergoing posterior fixation of the lumbosacral spine (PSF).

Hospital practice (1995)·2025
Same journal

The impact of hospitalist experience on patient outcomes: a retrospective cohort analysis at an academic medical center.

Hospital practice (1995)·2025
Same journal

The efficacy of melatonin as a preoperative anxiolytic in real-world setting: a randomized controlled trial.

Hospital practice (1995)·2025
Same journal

Antibiotic prescription patterns among hospitalized patients with influenza: a cross-sectional study in a tertiary referral hospital in Iran.

Hospital practice (1995)·2025
See all related articles

Even with successful treatment, patients may still carry stable human immunodeficiency virus (HIV) reservoirs. Complete HIV eradication is unlikely with current agents, necessitating novel drug strategies and vaccine development.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Successfully treated patients with no detectable plasma viremia can still harbor stable human immunodeficiency virus (HIV) reservoirs.
  • These reservoirs may persist in sites protected by blood-tissue barriers, complicating eradication efforts.

Purpose of the Study:

  • To highlight the persistence of HIV reservoirs despite effective treatment.
  • To emphasize the need for innovative therapeutic and preventative strategies against HIV.

Main Methods:

  • This study is a review of current understanding regarding HIV reservoirs and treatment limitations.
  • It synthesizes findings on viral persistence and the challenges in achieving complete eradication.

Main Results:

Related Experiment Videos

  • Stable HIV reservoirs persist in treated individuals, even without detectable viremia.
  • Current therapeutic agents are insufficient for complete HIV eradication.

Conclusions:

  • Achieving complete HIV eradication requires novel pharmacologic approaches.
  • Development of a safe and effective HIV vaccine remains a critical goal.